Potential Role of TGF-β in Diabetic Nephropathy
Mineral and Electrolyte Metabolism · 1998
DOI: 10.1159/000057369 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mineral and Electrolyte Metabolism, 1998. Verfasst von B B Hoffman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Penn Center for Molecular Studies of Kidney Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. Hauptthemen laut MEDLINE: Diabetic Nephropathies. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Renal injury in diabetes mellitus is a major cause of morbidity and mortality. Several manifestations of diabetic nephropathy may be a consequence of altered production and/or response to cytokines or growth factors. Transforming growth factor-β (TGF-β) is one such factor because it promotes renal cell hypertrophy and regulates the production of extracellular matrix molecules. In addition, high ambient glucose increases TGF-β1 mRNA and protein level in cultured proximal tubular cells and glomerular epithelial and mesangial cells. Neutralizing anti-TGF-β antibodies or antisense TGF-β1 oligodeoxynucleotides prevents the hypertrophic effects of high glucose and the stimulation of matrix synthesis in renal cells. Several reports have described overexpression of TGF-β in the glomeruli and tubulointerstitium of experimental and human diabetes mellitus. We recently provided evidence that the kidney in diabetic patients displays net renal production of immunoreactive TGF-β1, whereas there is net renal extraction in nondiabetic subjects. We also demonstrated that short-term treatment of streptozotocin-diabetic mice with neutralizing monoclonal antibody directed against TGF-β significantly reduces kidney weight and glomerular hypertrophy, and attenuates the increase in extracellular matrix mRNA levels. The factors that mediate increased renal TGF-β activity involve hyperglycemia per se and the intermediary action of other potent mediators such as angiotensin II, thromboxane, endothelins, and platelet-derived growth factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Penn Center for Molecular Studies of Kidney Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Hoffman, B. B., Sharma, K., & Ziyadeh, F. N. (1998). Potential Role of TGF-β in Diabetic Nephropathy. Mineral and Electrolyte Metabolism. https://doi.org/10.1159/000057369
Vancouver
Hoffman BB, Sharma K, Ziyadeh FN. Potential Role of TGF-β in Diabetic Nephropathy. Mineral and Electrolyte Metabolism. 1998. doi:10.1159/000057369
BibTeX
@article{Hoffman1998,
author = {Hoffman, B B and Sharma, K and Ziyadeh, F N},
title = {Potential Role of TGF-β in Diabetic Nephropathy},
journal = {Mineral and Electrolyte Metabolism},
year = {1998},
doi = {10.1159/000057369}
}
EUVIMED